Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone.

It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases.

[1][2][3][4] In January 2024, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L.

[5] In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone.

[5] Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy.